Navigation Links
Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3
Date:11/14/2007

VANCOUVER, Nov. 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) today announced its financial results for the three and nine months ended September 30, 2007, showing strong growth in sales and profits for its core antibiotic business. Meanwhile, the Company also announced the sale of its EPO operation to an unaffiliated party through a separate press release.

Highlights for the three and nine months ended September 30, 2007

-----------------------------------------------------------------

- Sales for the third quarter increased 102% to $23.10 million from

$11.41 million for the same period of 2006. Sales for the first nine

months reached $59.98 million, with an increase of 60% as compared to

the same period of 2006;

- Gross profit and gross margin for the third quarter were

$4.31 million and 18.66% compared to $0.73 million and 6.38% for the

same period of 2006;

- Operating income increased 347% to $1.31 million for this quarter

from a net loss of $0.53 million for same period of 2006;

- Net cash inflow generated from operating activities for the quarter

was $2.08 million, as compared to a net cash outflow of $1.23 million

for same period of 2006;

- Net income from continuing operations for the third quarter amounted

to $0.97 million, up 200% from a net loss of $0.97 million for the

same period of 2006;

- A net loss of $2.57 million was shown from discontinuing operations,

which was due to the impact of a $2.64 million non-cash impairment

charge of intangible assets and goodwill related to EPO disposal.

As the result of the EPO disposal, the Company will be focusing on core antibiotic business with vertical product lines covering intermediates, active pharmaceutical ingredients and formulation drugs, which all grew strongly over
'/>"/>

SOURCE Dragon Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
2. CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path
3. Akela Pharma Inc. Completes Share Consolidation
4. Cosmetic Bootcamp Solidifies Lead as Investor Symposium for Aesthetic Medicine
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Nurses From Across Nation Join Solidarity Caravan in Support of Striking Kentucky RNs
7. Smoking may strongly increase long-term risk of eye disease
8. Diabetes appears to increase risk of death for patients with acute coronary syndromes
9. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
10. Fat on chest and upper back increases risk of insulin resistance
11. Ability to cope with stress can increase good cholesterol in older white men, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... The brain plays a central role in regulating appetite ... important in the brain,s control of food intake and ... this process has been unclear. A new ... demonstrates that PPARγ activity in a type of neuron ... the response to high-fat diet. Sabrina Diano and ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay ... may have significantly less endurance than those who weigh less, a ... half were obese, half were of normal weight -- people who ... longer. Obesity also was associated with less strength, increased discomfort ... 50 to 65 years of age -- neither improved nor reduced ...
(Date:8/1/2014)... U.S. Food and Drug Administration announced on Friday that ... type 2 diabetes. Jardiance (empagliflozin) "can be ... control blood sugar levels in the overall management of ... Drug Evaluation II in the FDA,s Center for Drug ... The FDA also recommended that Jardiance be used along ...
(Date:8/1/2014)... a first-of-its-kind study, researchers at University Hospitals Rainbow Babies ... may be at greater risk for death on a ... on flights worldwide between January 2010 and June 2013 ... under the age of 2. , The study ... rare event of an in-flight pediatric fatality onboard commercial ...
(Date:8/1/2014)... August 01, 2014 Summer is here, and ... active during the summer, and they can be a pain ... ready to help all their customers get rid of ticks ... and 6,000 eggs in the summer, which is why they ... in tall grass and woodland areas and carry a number ...
Breaking Medicine News(10 mins):Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2Health News:Tis the Season for Tick Prevention 2
... ROCM ) will announce quarterly results after,financial markets ... hold a quarterly conference call to discuss its earnings ... (5:00 p.m. eastern time)., This call is being ... website at http://www.rocm.com . To listen live to ...
... China, Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... "the Company") (Nasdaq: CSKI ), a,leading ... the People,s Republic of China ("PRC"), announced ... purchase a proprietary breast drug from,Harbin Medical ...
... The Los Angeles Shambhala Center,presents a public talk and Zen ... 30 and November 1st and 2nd., This 20th generation ... the first time in Los Angeles at the Shambhala Meditation ... Colorado Blvd.,in Eagle Rock., On Thursday, October 30th, Shibata ...
... 28 /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: RBM, OTCBB: ... an initial closing of the financing announced on ... raising gross proceeds of $4.66,million. The closing involved ... at a price of $0.15 for each unit. ...
... series, Debating Health: Election 2008, the Harvard Public Opinion Research ... Harris Interactive conducted a new survey focused on whether voters ... great deal of difference" in the state of the nation,s ... been made of voter cynicism in recent times, a majority ...
... that was 29 days or older faced twice the risk ... receive a transfusion of stored blood that is 29 days ... more serious infections compared to those who get "fresher" blood, ... current U.S. regulations set the upper limit for blood storage ...
Cached Medicine News:Health News:Rochester Medical Announces Fourth Quarter 2008 Earnings Conference Call November 6, 2008 2Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 2Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 3Health News:Renowned Kyudo (Zen archery) Master Kanjuro Shibata Sensei to Present in L.A. 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 4Health News:Majority of voters say election outcome will make a great deal of difference on key issues 2Health News:Majority of voters say election outcome will make a great deal of difference on key issues 3Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 2Health News:Older Blood Boosts Chances of Infection in Transfusion Patients 3
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories Ltd., ... active pharmaceutical ingredients (APIs), complex intermediates and ... in 85 countries, today announced financial results for ... ended June 30, 2014. "Neuland,s results ... flow re-prioritization to accommodate certain customer needs, and ...
(Date:8/1/2014)... Aug. 1, 2014 Dyadic International, Inc. ("Dyadic") ... proprietary technologies are used to develop, manufacture and sell ... biopharmaceutical and industrial enzyme industries, announced today that it ... ended June 30, 2014 after market close on Thursday, ... that day at 5:00 p.m. Eastern Time to discuss ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, ... of Treatment , , SAN DIEGO, June ... its Phase 2 clinical trial evaluating the safety and ... the treatment of severe complicated skin and skin structure ...
... sets to be released-- , , PARIS, ... in patients with blepharospasm and cervical dystonia -- one placebo-controlled ... presented at the Movement Disorder Society (MDS) 13th annual International ... Pharmaceuticals, which plans to file a Biologic License Application (BLA) ...
Cached Medicine Technology:Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 2Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 3Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 4Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: